Von Willebrand factor (vWF) mediates platelet adhesion to injured endothelium, the first step in hemostasis, and helps maintain factor VIII levels. When vWF is deficient, patients have a bleeding disorder called von Willebrand disease (vWD).
| Inventor | Institute |
|---|---|
| Jacqueline Cordell | University of Oxford |
| Cat. #: | 152836 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Stem cell biology;Tissue-specific biology |
| Application: | IHC ; WB |
| Target: | Factor VIII-related antigen (Von Willebrand factor / vWf) |
| Reactivity: | Human |
| Clone: | F8/86 |
| Host: | Mouse |
| Class: | Monoclonal |
| Product description: | Von Willebrand factor (vWF) mediates platelet adhesion to injured endothelium, the first step in hemostasis, and helps maintain factor VIII levels. When vWF is deficient, patients have a bleeding disorder called von Willebrand disease (vWD). |
|---|---|
| Conjugation: | Unconjugated |
| Isotype: | IgG1 |
| Immunogen: | Von Willebrand factor isolated from human plasma |
| Myeloma used: | P3/NS1/1-Ag4.1 |
| Target background: | Von Willebrand factor (vWF) mediates platelet adhesion to injured endothelium, the first step in hemostasis, and helps maintain factor VIII levels. When vWF is deficient, patients have a bleeding disorder called von Willebrand disease (vWD). |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 0.9-1.1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Ellis et al. 2012. J Oncol. 2012:651507. PMID: 22545050. Angiogenesis in Paget's Disease of the Vulva and the Breast: Correlation with Microvessel Density. Hussein et al. 2009. Leukemia. 23(5):852-5. PMID: 19194467. MPLW515L mutation in acute megakaryoblastic leukaemia. Disse et al. 2009. Blood. 113(4):973-80. PMID: 18945966. Phospholipase D1 is specifically required for regulated secretion of von Willebrand factor from endothelial cells. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151030 | Anti-Progesterone [11P14] |
Key Info
Anti-Progesterone [11P14]
|
View Tool | |||||||||||||||||||
| 151027 | Anti-HSVICP8 [10A3] |
Key Info
Anti-HSVICP8 [10A3]
|
View Tool | |||||||||||||||||||
| 151031 | Anti-RuvA [RuvA 12C6] |
Key Info
Anti-RuvA [RuvA 12C6]
|
View Tool | |||||||||||||||||||
| 151035 | Anti-CD8 [14] mAb |
Key Info
Anti-CD8 [14] mAb
|
View Tool | |||||||||||||||||||
| 151018 | Anti-Mos [R38.1] |
Key Info
Anti-Mos [R38.1]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.